Stock Track | Tempus AI Sinks 5.36% in Pre-Market as Preliminary Results Show CRO Revenue Softness

Stock Track

01-13

Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.

While Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.

Eric Lefkofsky, Tempus' Founder and CEO, stated, "Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year." This admission of weakness in the CRO segment likely contributed to the stock's pre-market decline, despite the company's overall revenue growth and continued improvement in adjusted EBITDA.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1158779546"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158779546\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1158779546?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-13 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158779546","market":"us","top_or_hot":-1,"title":"Stock Track | Tempus AI Sinks 5.36% in Pre-Market as Preliminary Results Show CRO Revenue Softness","media":"Stock Track","content":"<html><body><p>Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.</p>\n<p>While Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.</p>\n<p>Eric Lefkofsky, Tempus' Founder and CEO, stated, \"Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year.\" This admission of weakness in the CRO segment likely contributed to the stock's pre-market decline, despite the company's overall revenue growth and continued improvement in adjusted EBITDA.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | Tempus AI Sinks 5.36% in Pre-Market as Preliminary Results Show CRO Revenue Softness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Sinks 5.36% in Pre-Market as Preliminary Results Show CRO Revenue Softness\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-01-13 21:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.</p>\n<p>While Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.</p>\n<p>Eric Lefkofsky, Tempus' Founder and CEO, stated, \"Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year.\" This admission of weakness in the CRO segment likely contributed to the stock's pre-market decline, despite the company's overall revenue growth and continued improvement in adjusted EBITDA.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1158779546","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158779546","pubTimestamp":1736773582,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.While Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract rese","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"股票赛道Tempus AI盘前下跌5.36%，初步结果显示CRO收入疲软","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Tempus AI, a precision medicine and AI technology company, saw its stock plunge 5.36% in pre-market trading on Monday. This decline followed the company's announcement of preliminary unaudited financial results for the fourth quarter and full year 2024.\nWhile Tempus reported an expected revenue growth of around 30% year-over-year to approximately $693 million for the full year 2024 and a 35% increase in Q4 2024 revenue to around $200 million, the company acknowledged softness in its contract research organization (CRO) revenues.\nEric Lefkofsky, Tempus' Founder and CEO, stated, \"Despite some softness in our CRO revenues, our core businesses gained momentum throughout the year.\" This admission of weakness in the CRO segment likely contributed to the stock's pre-market decline, despite the company's overall revenue growth and continued improvement in adjusted EBITDA.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}